Topline results from palm 007 study of siga's tecovirimat in treatment of mpox released

New york, aug. 15, 2024 (globe newswire) -- the national institutes of health's (nih) national institute of allergy and infectious diseases (niaid) today announced topline results from a preliminary analysis of the palm 007 (tecovirimat for treatment of monkeypox virus) clinical trial (nct05559099). niaid reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the democratic republic of the congo (drc) with monkeypox (mpox), who were administered siga's tecovirimat, a highly targeted antiviral treatment, versus placebo. all patients in this study were hospitalized for the entire duration of treatment. this study was not a registration study conducted under an u.s. fda investigational new drug application.
SIGA Ratings Summary
SIGA Quant Ranking